pyridopyrimidine - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	pyridopyrimidine	go back to main search page
Accession:	CHEBI:38932	browse the term
Definition:	Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring.
Synonyms:	related_synonym:	pyridopyrimidines

show annotations for term's descendants Sort by:
Rat (879) Mouse (892) Human (1007) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (879)

Ku-0063794

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

Ku 0063794 results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with AZD 6244] results in decreased phosphorylation of EIF4EBP1 protein; [Ku 0063794 co-treated with mirdametinib] results in decreased phosphorylation of EIF4EBP1 protein; Ku 0063794 inhibits the reaction [dactolisib results in decreased phosphorylation of EIF4EBP1 protein]

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

ribosomal protein S6

multiple interactions
decreases phosphorylation

[Ku 0063794 co-treated with 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] results in decreased phosphorylation of RPS6 protein
Ku 0063794 results in decreased phosphorylation of RPS6 protein

PMID:22415236 PMID:22885370

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

palbociclib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

palbociclib results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

BMS 754807 inhibits the reaction [palbociclib results in increased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein]

PMID:23676220 PMID:24986516

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

anillin, actin binding protein

decreases expression

palbociclib results in decreased expression of ANLN mRNA

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

apolipoprotein E

increases expression

palbociclib results in increased expression of APOE mRNA

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

anti-silencing function 1B histone chaperone

decreases expression

palbociclib results in decreased expression of ASF1B mRNA

NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549

G

aurora kinase A

decreases expression

palbociclib results in decreased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

decreases expression

palbociclib results in decreased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

BRCA1 associated RING domain 1

decreases expression

palbociclib results in decreased expression of BARD1 mRNA

PMID:22869556 PMID:28620137

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

baculoviral IAP repeat-containing 5

decreases expression

palbociclib results in decreased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bora, aurora kinase A activator

decreases expression

palbociclib results in decreased expression of BORA mRNA

NCBI chr15:75,797,624...75,835,599
Ensembl chr15:75,797,891...75,821,322

G

BUB1 mitotic checkpoint serine/threonine kinase

decreases expression

palbociclib results in decreased expression of BUB1 mRNA

NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650

G

caspase 3

multiple interactions
increases cleavage
decreases cleavage

[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP3 protein]
palbociclib results in increased cleavage of CASP3 protein
[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein
palbociclib results in decreased cleavage of CASP3 protein

PMID:22302033 PMID:22751436 PMID:23676220 PMID:24098593 PMID:27099147

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions

palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Carboplatin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Etoposide results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Paclitaxel results in increased activity of CASP7 protein]
[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein

PMID:22302033 PMID:24098593

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

cellular communication network factor 1

increases expression

palbociclib results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin A2

decreases expression
multiple interactions

palbociclib results in decreased expression of CCNA2 mRNA; palbociclib results in decreased expression of CCNA2 protein
E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]

PMID:20100483 PMID:20473330 PMID:21367843 PMID:21593195 PMID:22751436 More...

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

decreases expression

palbociclib results in decreased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

decreases expression

palbociclib results in decreased expression of CCNB2 mRNA

PMID:22869556 PMID:28620137

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin D1

decreases response to substance
multiple interactions
increases expression

CCND1 gene results in decreased susceptibility to palbociclib
[CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib
palbociclib results in increased expression of CCND1 protein
[BMS 754807 co-treated with palbociclib] results in increased expression of CCND1 protein; Doxorubicin inhibits the reaction [palbociclib results in increased expression of CCND1 protein]; palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein]

PMID:20473330 PMID:21278246 PMID:22094256 PMID:22751436 PMID:22869556 More...

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

multiple interactions

[CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin D3

multiple interactions
increases expression

palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]
[CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib
palbociclib results in increased expression of CCND3 protein

PMID:20473330 PMID:22094256 PMID:24098593

NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371

G

cyclin E1

decreases response to substance
decreases expression
increases expression

CCNE1 protein results in decreased susceptibility to palbociclib
palbociclib results in decreased expression of CCNE1 protein
palbociclib results in increased expression of CCNE1 protein

PMID:17537993 PMID:21278246 PMID:21880723 PMID:23708653

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin E2

decreases expression

palbociclib analog results in decreased expression of CCNE2 mRNA; palbociclib results in decreased expression of CCNE2 mRNA

PMID:15542782 PMID:22869556 PMID:26318986

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin F

decreases expression

palbociclib results in decreased expression of CCNF mRNA

PMID:22869556 PMID:24606660

NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101

G

cell division cycle 20

decreases expression

palbociclib results in decreased expression of CDC20 mRNA

NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512

G

cell division cycle 25A

decreases expression

palbociclib results in decreased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

decreases expression

palbociclib results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cell division cycle 37, HSP90 cochaperone

multiple interactions

palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein]

NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809

G

cell division cycle 45

decreases expression

palbociclib results in decreased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle associated 3

decreases expression

palbociclib results in decreased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 5

decreases expression

palbociclib results in decreased expression of CDCA5 mRNA

NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 8

decreases expression

palbociclib results in decreased expression of CDCA8 mRNA

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 1

affects localization
multiple interactions

palbociclib affects the localization of CDH1 protein
CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein]

PMID:22094256 PMID:22869556

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions
increases expression

2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDH2 protein]

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin-dependent kinase 1

decreases expression

palbociclib analog results in decreased expression of CDK1 mRNA; palbociclib results in decreased expression of CDK1 mRNA

PMID:15542782 PMID:22869556 PMID:24606660

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

decreases activity
multiple interactions
decreases phosphorylation
decreases expression

palbociclib results in decreased activity of CDK2 protein
palbociclib results in increased phosphorylation of and results in increased expression of CDK2 protein
palbociclib results in decreased phosphorylation of CDK2 protein
palbociclib results in decreased expression of CDK2 protein

PMID:17537993 PMID:20100483 PMID:20473330 PMID:21880723 PMID:22869556

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases response to substance
decreases activity
multiple interactions
increases expression
increases response to substance

CDK4 protein results in decreased susceptibility to palbociclib
palbociclib results in decreased activity of CDK4 protein
[CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib
palbociclib results in increased expression of CDK4 protein
palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK4 protein]; palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]; palbociclib promotes the reaction [CDK4 protein binds to CCND1 protein]
CDK4 protein results in increased susceptibility to palbociclib

PMID:20473330 PMID:22094256 PMID:22711607 PMID:22761470 PMID:22869556 More...

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 6

multiple interactions
increases expression

palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]; palbociclib inhibits the reaction [CDC37 protein binds to CDK6 protein]
palbociclib results in increased expression of CDK6 protein
[CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib

PMID:20473330 PMID:22094256 PMID:22869556 PMID:23138228 PMID:24098593 More...

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase 7

increases expression

palbociclib results in increased expression of CDK7 mRNA

NCBI chr 2:31,840,558...31,865,422
Ensembl chr 2:31,840,558...31,865,383

G

cyclin-dependent kinase inhibitor 1A

increases expression

palbociclib results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
increases expression
decreases expression

palbociclib promotes the reaction [CCND1 protein binds to CDKN1B protein binds to CDK4 protein]
palbociclib results in increased expression of CDKN1B mRNA; palbociclib results in increased expression of CDKN1B protein
palbociclib results in decreased expression of CDKN1B protein

PMID:17537993 PMID:20473330

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

affects response to substance
increases response to substance
multiple interactions
decreases response to substance

CDKN2A gene modified form affects the susceptibility to palbociclib; CDKN2A gene mutant form affects the susceptibility to palbociclib; CDKN2A protein affects the susceptibility to palbociclib
CDKN2A gene mutant form results in increased susceptibility to palbociclib
[CDKN2A gene mutant form results in increased expression of CCND1 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND2 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CCND3 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK4 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased expression of CDK6 protein] which results in increased susceptibility to palbociclib; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP3 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which affects the activity of CASP7 protein; [CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein
CDKN2A protein results in decreased susceptibility to palbociclib
[CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib

PMID:20534551 PMID:21278246 PMID:22711607 PMID:24098593 PMID:24495407

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cyclin-dependent kinase inhibitor 2B

increases expression
multiple interactions
decreases response to substance

palbociclib results in increased expression of CDKN2B protein
2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CDKN2B protein]
CDKN2B protein results in decreased susceptibility to palbociclib

PMID:22711607 PMID:22869556

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 2C

multiple interactions

[CDKN2A protein co-treated with CDKN2C protein] affects the susceptibility to palbociclib

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

cyclin-dependent kinase inhibitor 3

decreases expression

palbociclib results in decreased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

chromatin licensing and DNA replication factor 1

decreases expression

palbociclib results in decreased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

centromere protein A

decreases expression

palbociclib results in decreased expression of CENPA mRNA

NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675

G

centromere protein E

decreases expression

palbociclib results in decreased expression of CENPE mRNA

NCBI chr 2:223,637,035...223,695,692
Ensembl chr 2:223,636,998...223,695,669

G

centromere protein F

decreases expression

palbociclib results in decreased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

centromere protein M

decreases expression

palbociclib results in decreased expression of CENPM mRNA

NCBI chr 7:113,748,026...113,759,296
Ensembl chr 7:113,747,516...113,764,258

G

centrosomal protein 55

decreases expression

palbociclib results in decreased expression of CEP55 mRNA

NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394

G

cytoskeleton associated protein 2-like

decreases expression

palbociclib results in decreased expression of CKAP2L mRNA

NCBI chr 3:116,497,186...116,524,302
Ensembl chr 3:116,498,022...116,524,366

G

carboxypeptidase A4

increases expression

palbociclib results in increased expression of CPA4 mRNA

NCBI chr 4:59,188,284...59,212,255
Ensembl chr 4:59,188,284...59,212,255

G

catenin beta 1

multiple interactions
increases expression

2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

DENN domain containing 6B

increases expression

palbociclib results in increased expression of DENND6B mRNA

NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494

G

DEP domain containing 1B

decreases expression

palbociclib results in decreased expression of DEPDC1B mRNA

NCBI chr 2:39,891,163...39,963,779
Ensembl chr 2:39,891,481...39,963,779

G

DLG associated protein 5

decreases expression

palbociclib results in decreased expression of DLGAP5 mRNA

NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518

G

DNA replication fork stabilization factor DONSON

decreases expression

palbociclib results in decreased expression of DONSON mRNA

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

E2F transcription factor 1

multiple interactions

palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

E2F transcription factor 2

multiple interactions
decreases expression

E2F2 protein inhibits the reaction [palbociclib results in decreased expression of CCNA2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased expression of RNR2 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein]
palbociclib results in decreased expression of E2F2 mRNA

PMID:20100483 PMID:20473330 PMID:22869556

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

elastin

increases expression

palbociclib results in increased expression of ELN protein

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

exonuclease 1

decreases expression

palbociclib results in decreased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases expression

palbociclib results in decreased expression of EZH2 mRNA; palbociclib results in decreased expression of EZH2 protein

PMID:20948315 PMID:22869556 PMID:24736461

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

coagulation factor III, tissue factor

increases expression

palbociclib results in increased expression of F3 mRNA

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

FAM111 trypsin like peptidase A

decreases expression

palbociclib results in decreased expression of FAM111A mRNA

NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547

G

family with sequence similarity 83, member D

decreases expression

palbociclib results in decreased expression of FAM83D mRNA

NCBI chr 3:147,421,941...147,441,211
Ensembl chr 3:147,421,908...147,441,192

G

FA complementation group E

decreases expression

palbociclib results in decreased expression of FANCE mRNA

NCBI chr20:6,369,416...6,386,631
Ensembl chr20:6,375,573...6,386,631

G

FA complementation group I

decreases expression

palbociclib results in decreased expression of FANCI mRNA

NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640

G

F-box protein 5

decreases expression

palbociclib results in decreased expression of FBXO5 mRNA

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

flap structure-specific endonuclease 1

decreases expression

palbociclib results in decreased expression of FEN1 mRNA

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

Fms related receptor tyrosine kinase 3

decreases expression
affects response to substance
decreases phosphorylation
multiple interactions

palbociclib results in decreased expression of FLT3 mRNA; palbociclib results in decreased expression of FLT3 protein
FLT3 protein affects the susceptibility to palbociclib
palbociclib results in decreased phosphorylation of FLT3 protein
[FLT3 protein affects the susceptibility to palbociclib] which results in decreased expression of FLT3 protein

NCBI chr12:7,623,930...7,699,474
Ensembl chr12:7,623,930...7,699,474

G

forkhead box M1

multiple interactions
decreases expression

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of FOXM1 protein]; CDH1 protein affects the reaction [palbociclib results in decreased expression of FOXM1 protein]; palbociclib results in decreased expression of and results in decreased activity of FOXM1 protein
palbociclib results in decreased expression of FOXM1 mRNA

PMID:22094256 PMID:22869556

NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684

G

GINS complex subunit 2

decreases expression

palbociclib results in decreased expression of GINS2 mRNA

NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339

G

glutaminase

increases expression

palbociclib results in increased expression of GLS mRNA

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

geminin, DNA replication inhibitor

decreases expression

palbociclib results in decreased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

G-protein signaling modulator 2

decreases expression

palbociclib results in decreased expression of GPSM2 mRNA

NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154

G

glutamic--pyruvic transaminase

increases secretion

palbociclib results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

H2A.X variant histone

multiple interactions
decreases phosphorylation

Doxorubicin inhibits the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Carboplatin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Etoposide results in increased expression of H2AX protein]; palbociclib inhibits the reaction [Paclitaxel results in increased expression of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]

PMID:22302033 PMID:22751436

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

Holliday junction recognition protein

decreases expression

palbociclib results in decreased expression of HJURP mRNA

NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728

G

high mobility group box 2

decreases expression

palbociclib results in decreased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
Ensembl chr 1:32,710,658...32,713,140

G

hyaluronan-mediated motility receptor

decreases expression

palbociclib results in decreased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

insulin-like growth factor 1 receptor

multiple interactions

[BMS 754807 co-treated with palbociclib] results in decreased phosphorylation of IGF1R protein

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

interleukin 20 receptor subunit beta

increases expression

palbociclib results in increased expression of IL20RB mRNA

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:100,980,383...101,009,942

G

inner centromere protein

decreases expression

palbociclib results in decreased expression of INCENP mRNA

NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265

G

kinesin family member 11

decreases expression

palbociclib results in decreased expression of KIF11 mRNA

NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766

G

kinesin family member 14

decreases expression

palbociclib results in decreased expression of KIF14 mRNA

NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164

G

kinesin family member 15

decreases expression

palbociclib results in decreased expression of KIF15 mRNA

NCBI chr 8:122,601,888...122,672,750
Ensembl chr 8:122,601,897...122,672,750

G

kinesin family member 20A

decreases expression

palbociclib results in decreased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 23

decreases expression

palbociclib results in decreased expression of KIF23 mRNA

NCBI chr 8:62,397,908...62,425,162
Ensembl chr 8:62,397,948...62,425,072

G

kinesin family member 2C

decreases expression

palbociclib results in decreased expression of KIF2C mRNA

NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637

G

kinesin family member 4A

decreases expression

palbociclib results in decreased expression of KIF4A mRNA

NCBI chr X:65,721,746...65,824,277
Ensembl chr X:65,721,779...65,824,139

G

kinesin family member C1

decreases expression

palbociclib results in decreased expression of KIFC1 mRNA

NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105

G

kallikrein 1-related peptidase C10

multiple interactions

palbociclib promotes the reaction [Dihydrotestosterone results in increased expression of KLK3 mRNA]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

kinetochore-localized astrin/SPAG5 binding protein

decreases expression

palbociclib results in decreased expression of KNSTRN mRNA

NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715

G

karyopherin subunit alpha 2

decreases expression

palbociclib results in decreased expression of KPNA2 mRNA

NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150

G

laminin subunit alpha 3

increases expression

palbociclib results in increased expression of LAMA3 mRNA

NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353

G

laminin subunit beta 3

increases expression

palbociclib results in increased expression of LAMB3 mRNA

NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405

G

laminin subunit gamma 2

increases expression

palbociclib results in increased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lamin B1

decreases expression

palbociclib results in decreased expression of LMNB1 mRNA

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

minichromosome maintenance 10 replication initiation factor

decreases expression

palbociclib results in decreased expression of MCM10 mRNA

NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364

G

minichromosome maintenance complex component 7

multiple interactions
decreases expression

RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein]
palbociclib results in decreased expression of MCM7 mRNA; palbociclib results in decreased expression of MCM7 protein

PMID:20473330 PMID:22869556

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

myocyte enhancer factor 2D

multiple interactions

palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of MEF2D protein]

NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457

G

maternal embryonic leucine zipper kinase

decreases expression

palbociclib results in decreased expression of MELK mRNA

NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937

G

marker of proliferation Ki-67

multiple interactions
decreases expression

Doxorubicin promotes the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]

PMID:15542782 PMID:22170262 PMID:22383795 PMID:22751436 PMID:23708653 More...

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

Max dimerization protein 4

increases expression

palbociclib results in increased expression of MXD4 mRNA

NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

palbociclib results in decreased expression of MYC protein

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

non-SMC condensin I complex, subunit D2

decreases expression

palbociclib results in decreased expression of NCAPD2 mRNA

NCBI chr 4:157,968,814...157,992,314
Ensembl chr 4:157,968,815...157,992,020

G

non-SMC condensin I complex, subunit G

decreases expression

palbociclib results in decreased expression of NCAPG mRNA

NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902

G

non-SMC condensin II complex, subunit G2

decreases expression

palbociclib results in decreased expression of NCAPG2 mRNA

NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159

G

NDC80 kinetochore complex component

decreases expression

palbociclib results in decreased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

NIMA-related kinase 2

decreases expression

palbociclib results in decreased expression of NEK2 mRNA

NCBI chr13:103,405,818...103,419,063
Ensembl chr13:103,405,819...103,419,051

G

nucleolar and spindle associated protein 1

decreases expression

palbociclib results in decreased expression of NUSAP1 mRNA

NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624

G

Opa interacting protein 5

decreases expression

palbociclib results in decreased expression of OIP5 mRNA

NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250

G

poly (ADP-ribose) polymerase 1

multiple interactions

[palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein; palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]

PMID:22751436 PMID:23676220

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PDZ binding kinase

decreases expression

palbociclib results in decreased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

PCNA clamp associated factor

decreases expression

palbociclib results in decreased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

proliferating cell nuclear antigen

decreases expression

palbociclib results in decreased expression of PCNA mRNA; palbociclib results in decreased expression of PCNA protein

PMID:20473330 PMID:22869556

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

platelet derived growth factor subunit B

multiple interactions

palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

PHD finger protein 19

decreases expression

palbociclib results in decreased expression of PHF19 mRNA

NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405

G

Pim-1 proto-oncogene, serine/threonine kinase

decreases expression

palbociclib results in decreased expression of PIM1 mRNA

NCBI chr20:7,554,921...7,559,174
Ensembl chr20:7,554,921...7,559,174

G

PICALM interacting mitotic regulator

decreases expression

palbociclib results in decreased expression of PIMREG mRNA

NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791

G

polo-like kinase 1

decreases expression
multiple interactions

palbociclib results in decreased expression of PLK1 mRNA
palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]

PMID:20100483 PMID:22869556

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

DNA polymerase alpha 2, accessory subunit

decreases expression

palbociclib results in decreased expression of POLA2 mRNA

NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase epsilon 2, accessory subunit

decreases expression

palbociclib results in decreased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

porcupine O-acyltransferase

increases expression

palbociclib results in increased expression of PORCN mRNA

NCBI chr X:14,285,864...14,298,481
Ensembl chr X:14,285,871...14,298,481

G

protein regulator of cytokinesis 1

decreases expression

palbociclib results in decreased expression of PRC1 mRNA

NCBI chr 1:134,250,086...134,271,765
Ensembl chr 1:134,250,081...134,271,765

G

DNA primase subunit 1

decreases expression

palbociclib results in decreased expression of PRIM1 mRNA

NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526

G

proline rich 11

decreases expression

palbociclib results in decreased expression of PRR11 mRNA

NCBI chr10:71,898,858...71,943,325
Ensembl chr10:71,901,202...71,921,012

G

serine protease 23

increases expression

palbociclib results in increased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

proline and serine rich coiled-coil 1

decreases expression

palbociclib results in decreased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

PTTG1 regulator of sister chromatid separation, securin

decreases expression

palbociclib results in decreased expression of PTTG1 mRNA

PMID:22869556 PMID:28620137

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

Rac GTPase-activating protein 1

decreases expression

palbociclib results in decreased expression of RACGAP1 mRNA

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

RAD51 associated protein 1

decreases expression

palbociclib results in decreased expression of RAD51AP1 mRNA

NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524

G

RAN binding protein 1

decreases expression

palbociclib results in decreased expression of RANBP1 mRNA

NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838

G

RB transcriptional corepressor 1

affects phosphorylation
decreases expression
increases response to substance
multiple interactions
affects response to substance
decreases response to substance
affects reaction
increases phosphorylation
decreases phosphorylation

palbociclib affects the phosphorylation of RB1 protein
palbociclib results in decreased expression of RB1 mRNA; palbociclib results in decreased expression of RB1 protein
RB1 protein results in increased susceptibility to palbociclib
[CDKN2A gene mutant form results in increased susceptibility to palbociclib] which results in decreased phosphorylation of RB1 protein
RB1 protein affects the susceptibility to palbociclib
BMS 754807 promotes the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; E2F2 protein inhibits the reaction [palbociclib results in decreased phosphorylation of RB1 protein]; palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RB1 protein]; palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib inhibits the reaction [bisphenol S results in increased phosphorylation of RB1 protein]; palbociclib promotes the reaction [RB1 protein binds to CCNA2 promoter]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RB1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of CCNA2 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of E2F1 protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of CCNA2 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MCM7 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of MKI67 protein]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of H2AX protein]; RB1 protein affects the reaction [palbociclib results in decreased phosphorylation of RB1 protein]
RB1 gene mutant form results in decreased susceptibility to palbociclib; RB1 mutant form results in decreased susceptibility to palbociclib
RB1 protein affects the reaction palbociclib
palbociclib results in increased phosphorylation of RB1 protein

PMID:15542782 PMID:16690963 PMID:17537993 PMID:19435910 PMID:19874578 More...

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

RB transcriptional corepressor like 1

multiple interactions
decreases expression

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [palbociclib results in decreased expression of RBL1 protein]; palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]; palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]; palbociclib promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased ubiquitination of RBL1 protein]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; palbociclib results in decreased phosphorylation of and results in decreased expression of RBL1 protein; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to CCNA2 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to PLK1 promoter]]; RB1 protein affects the reaction [palbociclib inhibits the reaction [RBL1 protein binds to RNR2 promoter]]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]; RB1 protein affects the reaction [palbociclib results in decreased expression of RBL1 protein]
palbociclib results in decreased expression of RBL1 mRNA; palbociclib results in decreased expression of RBL1 protein

PMID:20100483 PMID:20473330

NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330

G

RB transcriptional corepressor like 2

multiple interactions
decreases phosphorylation

palbociclib affects the reaction [RB1 mutant form results in increased expression of RBL2 protein]; palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of RBL2 protein]; palbociclib results in decreased phosphorylation of and results in increased expression of RBL2 protein; palbociclib results in increased expression of and results in increased stability of RBL2 protein
palbociclib results in decreased phosphorylation of RBL2 protein

PMID:20100483 PMID:20473330 PMID:22094256 PMID:26174628

NCBI chr19:15,876,852...15,923,632
Ensembl chr19:15,876,853...15,923,572

G

retinol dehydrogenase 5

increases expression

palbociclib results in increased expression of RDH5 mRNA

NCBI chr 7:1,341,172...1,346,863
Ensembl chr 7:1,340,934...1,351,558

G

replication factor C subunit 5

decreases expression

palbociclib results in decreased expression of RFC5 mRNA

NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312

G

ribosomal protein S29

increases expression

palbociclib results in increased expression of RPS29 mRNA

NCBI chr 6:87,635,229...87,636,627
Ensembl chr 6:87,635,230...87,636,636
Ensembl chr13:87,635,230...87,636,636

G

ribosomal protein S6 kinase B1

multiple interactions

palbociclib promotes the reaction [BMS 754807 results in decreased phosphorylation of RPS6KB1 protein]

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

ribonucleotide reductase catalytic subunit M1

decreases expression

palbociclib results in decreased expression of RRM1 mRNA

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

decreases expression

palbociclib results in decreased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

suppressor APC domain containing 2

decreases expression

palbociclib results in decreased expression of SAPCD2 mRNA

NCBI chr 3:8,186,089...8,195,119
Ensembl chr 3:8,187,266...8,192,546

G

SUMO specific peptidase 3

multiple interactions

palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of SENP3 protein]

NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593

G

serpin family E member 1

increases expression

palbociclib results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

SHOX homeobox 2

multiple interactions

palbociclib inhibits the reaction [[CDK4 protein binds to CCND1 protein] which results in increased phosphorylation of SHOX2 protein]

NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143

G

solute carrier family 16, member 4

increases expression

palbociclib results in increased expression of SLC16A4 mRNA

NCBI chr 2:194,911,075...194,933,162
Ensembl chr 2:194,911,236...194,933,117

G

structural maintenance of chromosomes 4

decreases expression

palbociclib results in decreased expression of SMC4 mRNA

NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571

G

snail family transcriptional repressor 2

multiple interactions
increases expression

2-(5-benzo(1,3)dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride inhibits the reaction [palbociclib results in increased expression of SNAI2 protein]

NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200

G

Sp1 transcription factor

multiple interactions

palbociclib inhibits the reaction [[PDGFB protein binds to PDGFB protein] inhibits the reaction [RB1 protein binds to SP1 protein]]; palbociclib promotes the reaction [RB1 protein binds to SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

secreted protein acidic and cysteine rich

increases expression

palbociclib results in increased expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

SPC24 component of NDC80 kinetochore complex

decreases expression

palbociclib results in decreased expression of SPC24 mRNA

NCBI chr 8:20,300,315...20,305,354
Ensembl chr 8:20,300,319...20,305,310

G

SPC25 component of NDC80 kinetochore complex

decreases expression

palbociclib results in decreased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

STIL, centriolar assembly protein

decreases expression

palbociclib results in decreased expression of STIL mRNA

NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730

G

stathmin 1

decreases expression

palbociclib results in decreased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

transforming, acidic coiled-coil containing protein 3

decreases expression

palbociclib results in decreased expression of TACC3 mRNA

NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219

G

transforming growth factor, beta 1

increases activity

palbociclib results in increased activity of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

thymidine kinase 1

decreases expression

palbociclib analog results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 mRNA; palbociclib results in decreased expression of TK1 protein

PMID:15542782 PMID:22170262 PMID:22869556

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920

G

thymopoietin

decreases expression

palbociclib results in decreased expression of TMPO mRNA

NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727

G

DNA topoisomerase I

decreases expression

palbociclib results in decreased expression of TOP1 mRNA

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

DNA topoisomerase II alpha

decreases expression
multiple interactions

palbociclib analog results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A mRNA; palbociclib results in decreased expression of TOP2A protein
palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]; RB1 protein affects the reaction [palbociclib inhibits the reaction [Doxorubicin results in increased expression of TOP2A protein]]

PMID:15542782 PMID:20948315 PMID:22751436 PMID:22869556

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

decreases response to substance

TP53 protein mutant form results in decreased susceptibility to palbociclib

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TPX2, microtubule nucleation factor

decreases expression

palbociclib results in decreased expression of TPX2 mRNA

NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468

G

trophinin associated protein

decreases expression

palbociclib results in decreased expression of TROAP mRNA

NCBI chr 7:130,233,534...130,242,369
Ensembl chr 7:130,234,544...130,242,365

G

tetratricopeptide repeat domain 14

increases expression

palbociclib results in increased expression of TTC14 mRNA

NCBI chr 2:116,653,543...116,665,072
Ensembl chr 2:116,653,595...116,664,158

G

Ttk protein kinase

decreases expression

palbociclib results in decreased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin, beta 4B class IVb

decreases expression

palbociclib results in decreased expression of TUBB4B mRNA

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

tubulin, beta 5 class I

decreases expression

palbociclib results in decreased expression of TUBB mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

thymidylate synthetase

decreases expression

palbociclib results in decreased expression of TYMS mRNA; palbociclib results in decreased expression of TYMS protein

PMID:20948315 PMID:22869556

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

ubiquitin-conjugating enzyme E2C

decreases expression

palbociclib results in decreased expression of UBE2C mRNA

NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339

G

ubiquitin-conjugating enzyme E2T

decreases expression

palbociclib results in decreased expression of UBE2T mRNA

NCBI chr13:46,403,352...46,413,854
Ensembl chr13:46,403,375...46,414,835

G

ubiquitin-like with PHD and ring finger domains 1

decreases expression

palbociclib results in decreased expression of UHRF1 mRNA

NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631

G

vimentin

increases expression

palbociclib results in increased expression of VIM protein

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

zinc finger E-box binding homeobox 1

multiple interactions

palbociclib inhibits the reaction [[CDK6 protein binds to CCND3 protein] which results in increased phosphorylation of ZEB1 protein]

NCBI chr17:51,948,948...52,116,018
Ensembl chr17:51,948,948...52,115,214

G

ZW10 interacting kinetochore protein

decreases expression

palbociclib results in decreased expression of ZWINT mRNA

NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957

paliperidone palmitate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects abundance
multiple interactions
increases export
increases transport
affects response to substance
decreases activity

ABCB1 gene polymorphism affects the abundance of Paliperidone Palmitate; ABCB1 protein affects the abundance of Paliperidone Palmitate
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Paliperidone Palmitate]
ABCB1A protein results in increased transport of Paliperidone Palmitate
ABCB1A protein affects the susceptibility to Paliperidone Palmitate
Paliperidone Palmitate results in decreased activity of ABCB1 protein
Paliperidone Palmitate inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased transport of Paliperidone Palmitate

PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17541883 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ABCB1B protein affects the susceptibility to Paliperidone Palmitate

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

decreases activity

Paliperidone Palmitate results in decreased activity of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily G member 2

multiple interactions

Paliperidone Palmitate inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

brain-derived neurotrophic factor

increases expression

Paliperidone Palmitate results in increased expression of BDNF mRNA

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects abundance

CYP2D6 gene polymorphism affects the abundance of Paliperidone Palmitate; CYP2D6 protein affects the abundance of Paliperidone Palmitate

PMID:10639689 PMID:15089809 PMID:17541883

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

dopamine receptor D2

multiple interactions
affects binding

Paliperidone Palmitate binds to and results in decreased activity of DRD2 protein
Paliperidone Palmitate binds to DRD2 protein

PMID:19713555 PMID:22437487

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

fatty acid desaturase 2

increases expression
multiple interactions

Paliperidone Palmitate results in increased expression of FADS2 mRNA
[Paliperidone Palmitate results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

5-hydroxytryptamine receptor 2A

affects binding
multiple interactions

Paliperidone Palmitate binds to HTR2A protein
Paliperidone Palmitate binds to and results in decreased activity of HTR2A protein

PMID:7520908 PMID:19713555 PMID:22437487

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 7

multiple interactions

[Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Paliperidone Palmitate binds to and results in decreased activity of HTR7 protein

PMID:18996971 PMID:19509219 PMID:20827463

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

interleukin 1 alpha

increases expression

Paliperidone Palmitate results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

Paliperidone Palmitate results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Paliperidone Palmitate results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

potassium voltage-gated channel subfamily H member 2

decreases activity

Paliperidone Palmitate results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

prolactin

increases expression

Paliperidone Palmitate results in increased expression of PRL protein

PMID:17460786 PMID:19825908

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

PD-166866

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

fibroblast growth factor 1

multiple interactions

PD 166866 inhibits the reaction [FGF1 protein results in increased abundance of Nitric Oxide]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA]; PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA]

PMID:15121739 PMID:15773903 PMID:16524372

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

Fibroblast growth factor receptor 1

decreases activity
multiple interactions

PD 166866 results in decreased activity of FGFR1 protein
PD 166866 inhibits the reaction [FGF1 protein results in increased expression of FGFR1 protein]; PD 166866 inhibits the reaction [FGFR1 protein results in increased phosphorylation of FGFR1 protein]

PMID:12805413 PMID:15522930 PMID:15773903

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

nerve growth factor

multiple interactions

PD 166866 inhibits the reaction [FGF1 protein results in increased expression of and results in increased secretion of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions

PD 166866 inhibits the reaction [FGF1 protein results in increased expression of NOS2 mRNA]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

periostin

multiple interactions

PD 166866 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA]

NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099

PD173074

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

baculoviral IAP repeat-containing 5

multiple interactions

[arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

cyclin D1

multiple interactions

[PKI 166 co-treated with PD 173074] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

fibroblast growth factor 1

multiple interactions

PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]

NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357

G

Fibroblast growth factor receptor 1

decreases activity
decreases expression
multiple interactions

PD 173074 results in decreased activity of FGFR1 protein
PD 173074 results in decreased expression of FGFR1 protein
[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[Crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]; Arsenic Trioxide promotes the reaction [PD 173074 results in decreased expression of FGFR1 protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of FGFR1 protein]

PMID:22683780 PMID:27794399

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 3

decreases activity

PD 173074 results in decreased activity of FGFR3 protein

NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341

G

fibroblast growth factor receptor 4

multiple interactions
decreases activity

PD 173074 inhibits the reaction [FGF1 protein results in increased phosphorylation of FGFR4 protein]
PD 173074 results in decreased activity of FGFR4 protein

PMID:15377668 PMID:15709206

NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242

G

glial cell derived neurotrophic factor

multiple interactions

PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased expression of GDNF mRNA]; PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased secretion of GDNF protein]

NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209

G

hepatocyte growth factor

multiple interactions

[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions
decreases expression

PD 173074 results in decreased phosphorylation of MAPK1 protein
PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased phosphorylation of MAPK1 protein]
PD 173074 results in decreased expression of MAPK1 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]

PMID:15029211 PMID:25953896 PMID:27794399 PMID:28797567

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions
decreases expression

PD 173074 results in decreased phosphorylation of MAPK3 protein
PD 173074 inhibits the reaction [Docosahexaenoic Acids results in increased phosphorylation of MAPK3 protein]
PD 173074 results in decreased expression of MAPK3 protein
PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]

PMID:15029211 PMID:25953896 PMID:27794399 PMID:28797567

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions

[PD 173074 results in decreased activity of FGFR1 protein] inhibits the reaction [[crizotinib results in decreased phosphorylation of MET protein] which results in increased expression of HGF protein]

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

poly (ADP-ribose) polymerase 1

multiple interactions

[arsenic trioxide co-treated with PD 173074] results in increased expression of PARP1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in increased expression of PARP1 protein modified form; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in increased expression of PARP1 protein modified form

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

PH domain and leucine rich repeat protein phosphatase 1

multiple interactions

PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK1 protein]; PD 173074 inhibits the reaction [PHLPP1 gene mutant form results in increased phosphorylation of MAPK3 protein]

NCBI chr13:22,308,532...22,530,978
Ensembl chr13:22,308,548...22,530,977

G

Raf-1 proto-oncogene, serine/threonine kinase

decreases expression
multiple interactions

PD 173074 results in decreased expression of RAF1 protein; PD 173074 results in decreased expression of RAF1 protein modified form
[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein; [arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form; [arsenic trioxide results in increased susceptibility to PD 173074] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein; [PD 173074 results in increased susceptibility to arsenic trioxide] which results in decreased expression of RAF1 protein modified form; arsenic trioxide promotes the reaction [PD 173074 results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein modified form]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[arsenic trioxide co-treated with PD 173074] results in decreased expression of RAF1 protein]

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

ribosomal protein S6 kinase B1

multiple interactions

[PKI 166 co-treated with PD 173074] results in decreased activity of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions
decreases expression

[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein; [Arsenic Trioxide results in increased susceptibility to PD 173074] which results in decreased expression of SRC protein; [PD 173074 results in increased susceptibility to Arsenic Trioxide] which results in decreased expression of SRC protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Arsenic Trioxide co-treated with PD 173074] results in decreased expression of SRC protein]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein modified form]; PD 173074 promotes the reaction [Arsenic Trioxide results in decreased expression of SRC protein]
PD 173074 results in decreased expression of SRC protein; PD 173074 results in decreased expression of SRC protein modified form

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

T-box transcription factor 3

multiple interactions

PD 173074 inhibits the reaction [afimoxifene results in increased expression of TBX3 protein]; PD 173074 inhibits the reaction [Estrogens results in increased expression of TBX3 protein]

NCBI chr12:36,879,924...36,894,849
Ensembl chr12:36,881,445...36,893,708

G

vascular endothelial growth factor A

multiple interactions

4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide promotes the reaction [PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]]; PD 173074 inhibits the reaction [Sodium Chloride results in increased expression of VEGFA mRNA]

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

pemirolast

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

calcitonin-related polypeptide alpha

multiple interactions

pemirolast inhibits the reaction [Paclitaxel results in increased expression of CALCA protein]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

tachykinin, precursor 1

multiple interactions
decreases secretion

pemirolast inhibits the reaction [Paclitaxel results in increased expression of TAC1 protein]; pemirolast inhibits the reaction [Paclitaxel results in increased secretion of TAC1 protein alternative form]
pemirolast results in decreased secretion of TAC1 protein

PMID:15033348 PMID:21233199 PMID:21539837

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

pipemidic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 4

increases transport

ABCC4 protein results in increased transport of Pipemidic Acid

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

risperidone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

affects abundance
affects response to substance
increases response to substance
multiple interactions
increases transport
increases export
decreases activity

ABCB1 gene polymorphism affects the abundance of Risperidone; ABCB1 protein affects the abundance of Risperidone
ABCB1 gene polymorphism affects the susceptibility to Risperidone; ABCB1 protein affects the susceptibility to Risperidone
ABCB1 protein results in increased susceptibility to Risperidone
Risperidone inhibits the reaction [ABCB1 protein results in decreased export of Doxorubicin]
ABCB1 protein results in increased transport of Risperidone
ABCB1A protein affects the susceptibility to Risperidone
ABCB1A protein results in increased export of Risperidone
Risperidone results in decreased activity of ABCB1 protein
ABCB1A protein results in increased transport of Risperidone
Cyclosporine inhibits the reaction [ABCB1A protein results in increased export of Risperidone]

PMID:15502009 PMID:16118767 PMID:16810505 PMID:16936711 PMID:17054409 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

affects response to substance

ABCB1B protein affects the susceptibility to Risperidone

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily G member 2

multiple interactions

Risperidone inhibits the reaction [ABCG2 protein results in increased transport of Mitoxantrone]; Risperidone inhibits the reaction [ABCG2 protein results in increased uptake of estrone sulfate]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

adiponectin, C1Q and collagen domain containing

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

brain-derived neurotrophic factor

decreases expression
multiple interactions

Risperidone results in decreased expression of BDNF mRNA
Risperidone inhibits the reaction [Rotenone results in decreased expression of BDNF mRNA]
BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

PMID:12393228 PMID:17442543 PMID:19997080

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

calmodulin 2

increases expression

Risperidone results in increased expression of CALM2 mRNA

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calcium/calmodulin-dependent protein kinase II alpha

decreases expression

Risperidone results in decreased expression of CAMK2A protein

NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994

G

calcium/calmodulin-dependent protein kinase IV

decreases expression

Risperidone results in decreased expression of CAMK4 protein

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calcium/calmodulin-dependent protein kinase kinase 1

decreases expression

Risperidone results in decreased expression of CAMKK1 protein

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498

G

calcium/calmodulin-dependent protein kinase kinase 2

decreases expression

Risperidone results in decreased expression of CAMKK2 protein

NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279

G

caspase 3

multiple interactions
increases activity

Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 7

multiple interactions
increases activity

Palmitic Acid promotes the reaction [Risperidone results in increased activity of CASP7 protein]

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729

G

CCAAT/enhancer binding protein alpha

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein]
Risperidone results in increased expression of CEBPA mRNA; Risperidone results in increased expression of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

cholinergic receptor, muscarinic 4

affects response to substance

CHRM4 affects the susceptibility to Risperidone

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

catechol-O-methyltransferase

increases expression

Risperidone results in increased expression of COMT mRNA

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

corticotropin releasing hormone

decreases expression

Risperidone results in decreased expression of CRH mRNA

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

catenin beta 1

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects metabolic processing
multiple interactions
affects abundance
decreases metabolic processing
decreases hydroxylation
affects response to substance
increases response to substance
increases metabolic processing

CYP2D6 gene polymorphism affects the metabolism of Risperidone; CYP2D6 protein affects the metabolism of Risperidone
CYP2D6 gene polymorphism affects the metabolism of and affects the abundance of Risperidone; CYP2D6 protein affects the metabolism of and affects the abundance of Risperidone
CYP2D6 gene polymorphism affects the abundance of Risperidone; CYP2D6 protein affects the abundance of Risperidone
CYP2D6 gene polymorphism results in decreased metabolism of Risperidone
CYP2D6 gene polymorphism results in decreased hydroxylation of Risperidone
CYP2D6 gene polymorphism affects the susceptibility to Risperidone; CYP2D6 protein polymorphism affects the susceptibility to Risperidone
CYP2D6 protein results in increased susceptibility to Risperidone
CYP2D6 protein results in increased metabolism of Risperidone

PMID:10639689 PMID:15089809 PMID:15260906 PMID:15565299 PMID:15669884 More...

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects response to substance

N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]
CYP3A4 gene polymorphism affects the susceptibility to Risperidone; CYP3A4 protein affects the susceptibility to Risperidone

PMID:19395426 PMID:21402137

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

affects abundance
increases metabolic processing

CYP3A5 gene polymorphism affects the abundance of Risperidone; CYP3A5 protein affects the abundance of Risperidone
CYP3A5 protein results in increased metabolism of Risperidone

PMID:18708991 PMID:20332423

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

dopamine receptor D2

multiple interactions
affects response to substance
increases response to substance
affects binding

Risperidone binds to and results in decreased activity of DRD2 protein
DRD2 gene polymorphism affects the susceptibility to Risperidone
DRD2 gene polymorphism results in increased susceptibility to Risperidone; DRD2 gene SNP results in increased susceptibility to Risperidone; DRD2 protein results in increased susceptibility to Risperidone
Risperidone binds to DRD2 protein
[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein; DRD2 protein affects the reaction [Risperidone results in increased expression of CTNNB1 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]; DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]; Risperidone binds to and results in decreased activity of DRD2 protein; Risperidone inhibits the reaction [Apomorphine binds to and results in increased activity of DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]

PMID:1380082 PMID:7520908 PMID:8804920 PMID:10831489 PMID:12191584 More...

NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875

G

dopamine receptor D3

increases response to substance

DRD3 gene SNP results in increased susceptibility to Risperidone; DRD3 protein results in increased susceptibility to Risperidone

PMID:19506579 PMID:19997080

NCBI chr11:56,879,689...56,931,901
Ensembl chr11:56,879,689...56,940,596

G

dishevelled segment polarity protein 3

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of DVL3 protein]

NCBI chr11:80,365,446...80,382,641
Ensembl chr11:80,366,117...80,382,462

G

early growth response 1

decreases expression

Risperidone results in decreased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

decreases expression
multiple interactions

Risperidone results in decreased expression of EGR2 protein
Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of EGR2 protein]]

PMID:17028028 PMID:32980479

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

erb-b2 receptor tyrosine kinase 2

increases phosphorylation

Risperidone results in increased phosphorylation of ERBB2 protein

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

Risperidone results in increased expression of and results in increased phosphorylation of ERBB4 protein

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

fatty acid desaturase 2

increases expression
multiple interactions

Risperidone results in increased expression of FADS2 mRNA
[Risperidone results in increased expression of FADS2 mRNA] which results in increased abundance of Fatty Acids, Unsaturated

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

Fas cell surface death receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Risperidone promotes the reaction [Rotenone results in increased expression of FOS mRNA]
Risperidone results in increased expression of FOS mRNA
Risperidone results in increased expression of FOS protein
Dronabinol inhibits the reaction [Risperidone results in increased expression of FOS protein]; Risperidone inhibits the reaction [Toluene promotes the reaction [4-iodo-2,5-dimethoxyphenylisopropylamine results in increased expression of FOS protein]]

PMID:11516571 PMID:17442543 PMID:28272498 PMID:32980479

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

affects expression

Risperidone affects the expression of FSHB protein

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

gamma-glutamyltransferase 1

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GGT1 protein]; Risperidone results in increased expression of and results in increased secretion of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GOT1 protein]; Risperidone results in increased expression of and results in increased secretion of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions

Acetylcysteine inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; coenzyme Q10 inhibits the reaction [Risperidone results in increased expression of and results in increased secretion of GPT protein]; Risperidone results in increased expression of and results in increased secretion of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 alpha

increases expression
multiple interactions

Risperidone results in increased expression of GSK3A protein
DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3A protein]

NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802

G

glycogen synthase kinase 3 beta

multiple interactions
increases expression

DRD2 protein affects the reaction [Risperidone results in increased expression of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

3-hydroxy-3-methylglutaryl-CoA reductase

increases expression

Risperidone results in increased expression of HMGCR mRNA

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

homer scaffold protein 1

increases expression

Risperidone results in increased expression of HOMER1 mRNA

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

5-hydroxytryptamine receptor 1A

increases response to substance
multiple interactions

HTR1A protein results in increased susceptibility to Risperidone
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide inhibits the reaction [HTR1A protein results in increased susceptibility to Risperidone]

NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442

G

5-hydroxytryptamine receptor 2A

increases response to substance
affects response to substance
multiple interactions
affects binding

HTR2A gene SNP results in increased susceptibility to Risperidone; HTR2A protein results in increased susceptibility to Risperidone
HTR2A protein affects the susceptibility to Risperidone
HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; Risperidone binds to and results in decreased activity of HTR2A protein
Risperidone binds to and results in decreased activity of HTR2A protein; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein]
Risperidone binds to HTR2A protein

PMID:7520908 PMID:11927170 PMID:12191584 PMID:16314884 PMID:16948927 More...

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

5-hydroxytryptamine receptor 2C

affects response to substance
increases response to substance
multiple interactions

HTR2C gene polymorphism affects the susceptibility to Risperidone; HTR2C protein affects the susceptibility to Risperidone
HTR2C protein results in increased susceptibility to Risperidone
HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

PMID:19142101 PMID:19997080

NCBI chr X:110,640,777...110,870,288
Ensembl chr X:110,641,153...110,870,287

G

5-hydroxytryptamine receptor 6

multiple interactions

HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]

NCBI chr 5:151,295,269...151,312,853
Ensembl chr 5:151,296,662...151,311,912

G

5-hydroxytryptamine receptor 7

multiple interactions

2-((2-(dimethylamino)ethyl)thio)-3-phenylquinoline inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; [Risperidone binds to and results in decreased activity of HTR7 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]; Clozapine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Cyproheptadine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; mesulergine inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Mianserin inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]; Risperidone binds to and results in decreased activity of HTR7 protein; SB 269970 inhibits the reaction [Risperidone binds to and results in decreased activity of HTR7 protein]

PMID:18996971 PMID:19509219 PMID:20827463

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626

G

inhibin subunit alpha

multiple interactions

Risperidone results in increased expression of [INHA protein binds to INHBB protein]

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

inhibin subunit beta B

multiple interactions

Risperidone results in increased expression of [INHA protein binds to INHBB protein]

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

insulin 2

increases expression

Risperidone results in increased expression of INS protein

PMID:11927762 PMID:16601995

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

Risperidone inhibits the reaction [KCNH2 protein results in increased transport of Thallium]

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

low density lipoprotein receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA]

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

monoamine oxidase A

affects response to substance
increases response to substance

MAOA gene polymorphism affects the susceptibility to Risperidone
MAOA protein results in increased susceptibility to Risperidone

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

monoamine oxidase B

increases expression

Risperidone results in increased expression of MAOB mRNA

NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003

G

microtubule-associated protein 2

increases expression

Risperidone results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

nerve growth factor receptor

decreases expression

Risperidone results in decreased expression of NGFR mRNA

PMID:12111809 PMID:16513140

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Risperidone promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

neuregulin 1

increases expression

Risperidone results in increased expression of NRG1 protein

NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884

G

peroxisome proliferator-activated receptor gamma

increases expression
multiple interactions

Risperidone results in increased expression of PPARG mRNA; Risperidone results in increased expression of PPARG protein
Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein phosphatase 3 catalytic subunit alpha

multiple interactions
decreases expression

[Risperidone binds to and results in decreased activity of DRD2 protein] which results in increased expression of PPP3CA protein
Risperidone results in decreased expression of PPP3CA mRNA; Risperidone results in decreased expression of PPP3CA protein

NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974

G

prolactin

multiple interactions
increases secretion
increases expression

[Risperidone co-treated with Clozapine] results in increased expression of PRL protein; Aripiprazole inhibits the reaction [Risperidone results in increased secretion of PRL protein]; BDNF gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2A gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR2C gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]; HTR6 gene polymorphism affects the reaction [Risperidone results in increased expression of PRL protein]
Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]

PMID:1380082 PMID:9696519 PMID:9989566 PMID:10084644 PMID:11048906 More...

NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062

G

regulator of G-protein signaling 2

increases expression

Risperidone results in increased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

S100 calcium binding protein B

increases secretion

Risperidone results in increased secretion of S100B protein

NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743

G

solute carrier family 17 member 6

increases expression

Risperidone results in increased expression of SLC17A6 mRNA; Risperidone results in increased expression of SLC17A6 protein

NCBI chr 1:101,212,489...101,252,543
Ensembl chr 1:101,212,489...101,252,542

G

synaptosome associated protein 25

affects response to substance

SNAP25 gene SNP affects the susceptibility to Risperidone

NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760

G

superoxide dismutase 1

multiple interactions
increases expression

Risperidone inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of SOD1 mRNA]; Risperidone inhibits the reaction [Haloperidol results in decreased expression of SOD1 protein]
Risperidone results in increased expression of SOD1 mRNA

PMID:12111809 PMID:12752374 PMID:16564057

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

sterol regulatory element binding transcription factor 1

multiple interactions
increases expression

Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein]
Risperidone results in increased expression of SREBF1 mRNA; Risperidone results in increased expression of SREBF1 protein

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 3

multiple interactions

Risperidone inhibits the reaction [Rotenone results in decreased expression of STAT3 mRNA]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tyrosine hydroxylase

increases expression

Risperidone results in increased expression of TH protein

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

sotorasib

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AADAT mRNA

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332

G

abhydrolase domain containing 11

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ABHD11 mRNA

NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398

G

acetylcholinesterase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACHE mRNA

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acid phosphatase 7, tartrate resistant

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACP7 mRNA

NCBI chr 1:83,896,485...83,923,436
Ensembl chr 1:83,898,153...83,920,634

G

acyl-CoA synthetase long-chain family member 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACSL5 mRNA

NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607

G

acyl-CoA synthetase medium-chain family member 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACSM3 mRNA

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

actin alpha 2, smooth muscle

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACTA2 mRNA

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actin, beta-like 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ACTBL2 mRNA

NCBI chr 2:42,858,020...42,860,767
Ensembl chr 2:42,858,020...42,860,767

G

aminoacylase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ACY3 mRNA

NCBI chr 1:201,279,751...201,285,803
Ensembl chr 1:201,279,851...201,283,175

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 16

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS16 mRNA

NCBI chr 1:32,430,436...32,562,481
Ensembl chr 1:32,430,436...32,560,494

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ADAMTS6 mRNA

NCBI chr 2:35,421,483...35,633,305
Ensembl chr 2:35,421,510...35,633,298

G

adhesion G protein-coupled receptor G1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

adhesion G protein-coupled receptor L3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ADGRL3 mRNA

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,368,277...27,105,860

G

adrenoceptor beta 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ADRB2 mRNA

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

actin filament associated protein 1-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AFAP1L1 mRNA

NCBI chr18:55,183,786...55,244,174
Ensembl chr18:55,183,786...55,244,146

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AGR2 mRNA

NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371

G

A-kinase anchoring protein 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AKAP5 mRNA

NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578

G

AT-hook transcription factor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AKNA mRNA

NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017

G

AKT serine/threonine kinase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AKT3 mRNA

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

aldehyde dehydrogenase 1 family, member A2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ALDH1A2 mRNA

NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107

G

aldolase, fructose-bisphosphate C

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ALDOC mRNA

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

arachidonate epidermal lipoxygenase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ALOXE3 mRNA

NCBI chr10:53,830,219...53,854,328
Ensembl chr10:53,831,264...53,854,328

G

alkaline phosphatase, germ cell

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ALPG mRNA

NCBI chr 9:87,748,721...87,761,500
Ensembl chr 9:87,753,648...87,757,836

G

antagonist of mitotic exit network 1 homolog

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AMN1 mRNA

NCBI chr 4:182,155,140...182,182,085
Ensembl chr 4:182,155,142...182,182,016

G

adenosine monophosphate deaminase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

angiogenin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANG mRNA

NCBI chr15:24,312,711...24,323,361

G

angiopoietin-like 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANK3 mRNA

NCBI chr20:18,602,267...19,225,831
Ensembl chr20:18,602,786...19,086,300

G

ankyrin repeat and EF-hand domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKEF1 mRNA

NCBI chr 3:123,847,832...123,883,060
Ensembl chr 3:123,847,817...123,883,059

G

ankyrin repeat domain 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKRD2 mRNA

NCBI chr 1:240,847,111...240,856,563
Ensembl chr 1:240,847,072...240,856,566

G

ankyrin repeat domain 24

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD24 mRNA

NCBI chr 7:8,061,634...8,081,142
Ensembl chr 7:8,061,953...8,081,142

G

ankyrin repeat domain 37

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANKRD37 mRNA

NCBI chr16:46,268,933...46,271,971
Ensembl chr16:46,268,443...46,271,963

G

ankyrin repeat domain 65

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ANKRD65 mRNA

NCBI chr 5:166,398,359...166,400,616
Ensembl chr 5:166,397,748...166,400,953

G

anoctamin 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANO7 mRNA

NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323

G

alanyl aminopeptidase, membrane

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ANPEP mRNA

NCBI chr 1:133,767,332...133,810,137
Ensembl chr 1:133,767,332...133,785,789

G

amine oxidase, copper containing 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of AOC3 mRNA

NCBI chr10:86,272,757...86,280,702

G

apelin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of APLN mRNA

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

apolipoprotein B receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of APOBR mRNA

NCBI chr 1:181,169,019...181,173,206
Ensembl chr 1:181,168,916...181,173,528

G

ARFGEF family member 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

Rho GTPase activating protein 31

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARHGAP31 mRNA

NCBI chr11:62,038,635...62,151,564
Ensembl chr11:62,038,635...62,151,564

G

Rho GTPase activating protein 8

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ARHGAP8 mRNA

NCBI chr 7:115,842,223...115,902,094
Ensembl chr 7:115,850,654...115,902,093

G

armadillo-like helical domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ARMH1 mRNA

NCBI chr 5:130,680,955...130,722,062
Ensembl chr 5:130,682,485...130,722,062

G

autophagy related 9B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATG9B mRNA

NCBI chr 4:10,784,934...10,793,832
Ensembl chr 4:10,786,114...10,793,651

G

ATPase phospholipid transporting 10D (putative)

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ATP10D mRNA

NCBI chr14:35,911,728...36,012,549
Ensembl chr14:35,912,141...36,012,564

G

ATPase 13A3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP13A3 mRNA

NCBI chr11:70,364,998...70,442,005
Ensembl chr11:70,365,322...70,441,235

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP2A3 mRNA

NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748

G

ATPase H+ transporting V0 subunit D2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

advillin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of AVIL mRNA

NCBI chr 7:62,825,459...62,844,103
Ensembl chr 7:62,826,025...62,844,071

G

BTB domain and CNC homolog 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BACH2 mRNA

NCBI chr 5:46,632,338...46,982,676
Ensembl chr 5:46,638,317...46,977,877

G

BMP and activin membrane-bound inhibitor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060

G

BARX homeobox 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BARX2 mRNA

NCBI chr 8:30,251,132...30,319,105
Ensembl chr 8:30,251,132...30,319,013

G

basic leucine zipper ATF-like transcription factor 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BATF3 mRNA

NCBI chr13:102,689,657...102,701,241
Ensembl chr13:102,689,657...102,701,139

G

Bcl2-like 14

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BCL2L14 mRNA

NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:167,219,871...167,258,086

G

beta-carotene oxygenase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BCO2 mRNA

NCBI chr 8:50,882,174...50,907,676
Ensembl chr 8:50,882,181...50,915,467

G

brain expressed X-linked 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BEX2 mRNA

NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958

G

BICD family like cargo adaptor 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BICDL2 mRNA

NCBI chr10:12,691,610...12,700,049
Ensembl chr10:12,691,610...12,700,049

G

bridging integrator 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BIN2 mRNA

NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285

G

BLACAT1 overlapping LEMD1 locus

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BLACAT1 mRNA

G

B-cell linker

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BLNK mRNA

NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113

G

bone morphogenetic protein 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

BLOC-1 related complex subunit 8

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BORCS8 mRNA

NCBI chr16:19,274,305...19,280,969
Ensembl chr16:19,274,023...19,280,339

G

betacellulin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BTC mRNA

NCBI chr14:16,708,447...16,746,961
Ensembl chr14:16,707,982...16,747,049

G

BTG anti-proliferation factor 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of BTG2 mRNA

NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628

G

similar to human chromosome 1 open reading frame 116

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of C1ORF116 mRNA

NCBI chr13:42,187,442...42,201,432
Ensembl chr13:42,188,609...42,201,426

G

similar to human chromosome 7 open reading frame 57

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of C7ORF57 mRNA

NCBI chr14:83,748,478...83,768,293
Ensembl chr14:83,748,478...83,767,435

G

complement C1r

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C1R mRNA

NCBI chr 4:157,412,718...157,423,483
Ensembl chr 4:157,412,692...157,423,484

G

complement C1s

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C1S mRNA

NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303

G

similar to human chromosome 15 open reading frame 48

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C15ORF48 mRNA

NCBI chr 3:109,719,952...109,723,505
Ensembl chr 3:109,719,897...109,724,006
Ensembl chr 3:109,719,897...109,724,006

G

complement C7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C7 mRNA

NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535

G

calcium voltage-gated channel subunit alpha1 D

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CACNA1D mRNA

NCBI chr16:5,227,157...5,521,163
Ensembl chr16:5,228,306...5,668,215

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CACNA1F mRNA

NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413

G

calcium voltage-gated channel auxiliary subunit beta 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CACNB4 mRNA

NCBI chr 3:36,906,771...37,169,165
Ensembl chr 3:36,910,427...37,168,944

G

calbindin 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CALB2 mRNA

NCBI chr19:38,114,435...38,141,438
Ensembl chr19:38,114,424...38,141,438

G

calpain 12

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CAPN12 mRNA

NCBI chr 1:84,171,059...84,183,161
Ensembl chr 1:84,171,059...84,183,119

G

calpain 8

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CAPN8 mRNA

NCBI chr13:94,252,218...94,316,146
Ensembl chr13:94,253,054...94,316,146

G

carbonic anhydrase 9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CA9 mRNA

NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838

G

caspase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CASP1 mRNA

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage

sotorasib results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catsper channel auxiliary subunit epsilon

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CATSPERE mRNA

NCBI chr13:89,799,669...89,954,723
Ensembl chr13:89,819,244...89,950,979

G

coiled-coil domain containing 110

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCDC110 mRNA

NCBI chr16:46,315,745...46,337,050
Ensembl chr16:46,315,745...46,337,021

G

coiled-coil domain containing 87

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCDC87 mRNA

NCBI chr 1:202,135,021...202,137,717
Ensembl chr 1:202,134,963...202,138,337

G

coiled-coil domain containing 89

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCDC89 mRNA

NCBI chr 1:144,386,252...144,387,514
Ensembl chr 1:144,386,158...144,389,850

G

C-C motif chemokine ligand 22

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

CCM2 like scaffold protein

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCM2L mRNA

NCBI chr 3:141,533,470...141,549,136
Ensembl chr 3:141,533,511...141,549,140

G

cyclin E2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

C-C motif chemokine receptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CCR1 mRNA

NCBI chr 8:123,556,286...123,561,841

G

CD22 molecule

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD22 mRNA

NCBI chr 1:86,116,376...86,132,782
Ensembl chr 1:86,117,459...86,132,322

G

CD274 molecule

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

Cd72 molecule

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CD72 mRNA

NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725

G

CD74 molecule

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CD74 mRNA

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

Cd82 molecule

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CD82 mRNA

NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809

G

CUB domain containing protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDCP1 mRNA

NCBI chr 8:122,828,685...122,865,345
Ensembl chr 8:122,828,685...122,865,388

G

cadherin 15

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDH15 mRNA

NCBI chr19:50,903,757...50,927,151
Ensembl chr19:50,903,638...50,927,105

G

cadherin 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDH3 mRNA

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1C

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

centromere protein S

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CENPS mRNA

NCBI chr 5:159,563,917...159,573,534

G

cilia and flagella associated protein 184

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CFAP184 mRNA

NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888

G

cilia and flagella associated protein 45

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP45 mRNA

NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878

G

cilia and flagella associated protein 92

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP92 mRNA

NCBI chr 4:120,126,565...120,181,575
Ensembl chr 4:120,126,567...120,181,546

G

cilia and flagella associated protein 96

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CFAP96 mRNA

NCBI chr16:46,291,075...46,315,616
Ensembl chr16:46,291,311...46,315,625

G

complement factor H

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CFH mRNA

NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838

G

chromodomain helicase DNA binding protein 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CHD7 mRNA

NCBI chr 5:21,812,007...21,995,358
Ensembl chr 5:21,812,070...21,995,358

G

CHD9 neighbor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHD9NB mRNA

G

chromogranin B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHGB mRNA

NCBI chr 3:120,043,824...120,057,169
Ensembl chr 3:120,043,738...120,057,166

G

cholinergic receptor, muscarinic 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CHRM4 mRNA

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor nicotinic alpha 10 subunit

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CHRNA10 mRNA

NCBI chr 1:156,487,279...156,494,277
Ensembl chr 1:156,487,279...156,491,476

G

circadian associated repressor of transcription

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CIART mRNA

NCBI chr 2:183,419,819...183,424,845
Ensembl chr 2:183,419,819...183,423,313

G

ciliary microtubule inner protein 2A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CIMIP2A mRNA

NCBI chr 3:8,030,548...8,038,370
Ensembl chr 3:8,033,246...8,037,961

G

claudin 9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CLDN9 mRNA

NCBI chr10:12,714,137...12,715,568

G

cornichon family AMPA receptor auxiliary protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CNIH2 mRNA

NCBI chr 1:202,399,416...202,405,110
Ensembl chr 1:202,399,419...202,405,089

G

collagen type XIII alpha 1 chain

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of COL13A1 mRNA

NCBI chr20:29,783,965...29,924,116
Ensembl chr20:29,783,965...29,924,032

G

collagen type I alpha 2 chain

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type V alpha 3 chain

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL5A3 mRNA

NCBI chr 8:19,304,564...19,349,809
Ensembl chr 8:19,304,571...19,349,853

G

collagen type VI alpha 3 chain

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of COL6A3 mRNA

NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471

G

collagen type IX alpha 2 chain

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COL9A2 mRNA

NCBI chr 5:134,607,616...134,624,678
Ensembl chr 5:134,607,616...134,624,677

G

collagen like tail subunit of asymmetric acetylcholinesterase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of COLQ mRNA

NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107

G

carboxypeptidase E

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CPE mRNA

NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233

G

calcium release activated channel regulator 2B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CRACR2B mRNA

NCBI chr 1:196,558,407...196,563,961
Ensembl chr 1:196,558,588...196,563,771

G

cAMP responsive element binding protein 3-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L1 mRNA

NCBI chr 3:77,952,589...77,993,513
Ensembl chr 3:77,952,540...77,993,456

G

cAMP responsive element binding protein 3-like 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREB3L3 mRNA

NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048

G

cellular repressor of E1A-stimulated genes 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CREG2 mRNA

NCBI chr 9:41,872,000...41,945,413
Ensembl chr 9:41,902,304...41,945,095

G

crystallin beta-gamma domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYBG1 mRNA

NCBI chr20:47,425,030...47,496,918
Ensembl chr20:47,426,183...47,621,392

G

crystallin, mu

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CRYM mRNA

NCBI chr 1:174,560,423...174,575,660
Ensembl chr 1:174,560,416...174,575,633

G

cysteine sulfinic acid decarboxylase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CSAD mRNA

NCBI chr 7:133,308,571...133,337,914
Ensembl chr 7:133,308,574...133,337,615

G

colony stimulating factor 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CSF3 mRNA

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

cathepsin C

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin L

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of CTSL mRNA

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin O

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CTSO mRNA

NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:167,230,330...167,253,702

G

C-X3-C motif chemokine ligand 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CX3CL1 mRNA

NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833

G

C-X-C motif chemokine ligand 10

increases expression

sotorasib results in increased expression of CXCL10 mRNA

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 11

increases expression

sotorasib results in increased expression of CXCL11 mRNA

NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271

G

cytochrome P450, family 26, subfamily b, polypeptide 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

DNA-damage-inducible transcript 4-like

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DDIT4L mRNA

NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375

G

DEXD/H-box helicase 60

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DDX60 mRNA

NCBI chr16:28,077,000...28,197,903
Ensembl chr16:28,076,999...28,179,526

G

DENN domain containing 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DENND3 mRNA

NCBI chr 7:105,415,870...105,473,583
Ensembl chr 7:105,415,677...105,473,592

G

DEPP autophagy regulator 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

DEP domain containing MTOR-interacting protein

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DEPTOR mRNA

NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773

G

dehydrogenase/reductase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DHRS2 mRNA

NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644

G

iodothyronine deiodinase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DIO2 mRNA

NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809

G

dickkopf WNT signaling pathway inhibitor 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DKK3 mRNA

NCBI chr 1:166,237,969...166,281,271
Ensembl chr 1:166,238,238...166,280,590

G

DLC1 Rho GTPase activating protein

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DLC1 mRNA

NCBI chr16:55,246,716...55,671,441
Ensembl chr16:55,291,584...55,671,439

G

dermokine

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DMKN mRNA

NCBI chr 1:86,013,237...86,031,243
Ensembl chr 1:86,014,188...86,030,006

G

dynein axonemal assembly factor 8

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DNAAF8 mRNA

NCBI chr10:10,600,747...10,614,891
Ensembl chr10:10,600,734...10,614,891

G

dynein, axonemal, heavy chain 11

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DNAH11 mRNA

NCBI chr 6:138,839,175...139,155,554
Ensembl chr 6:138,839,177...139,155,536

G

double C2 domain beta

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOC2B mRNA

NCBI chr10:60,628,029...60,653,267
Ensembl chr10:60,628,029...60,653,267

G

docking protein 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DOK3 mRNA

NCBI chr17:9,109,633...9,115,188
Ensembl chr17:9,109,597...9,115,188

G

dynein regulatory complex subunit 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DRC3 mRNA

NCBI chr10:45,149,094...45,200,659
Ensembl chr10:45,157,354...45,199,369

G

dual oxidase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of DUOX1 mRNA

NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563

G

dual oxidase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOX2 mRNA

NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902

G

dual oxidase maturation factor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUOXA1 mRNA

NCBI chr 3:109,249,815...109,260,511
Ensembl chr 3:109,249,923...109,260,499

G

dual specificity phosphatase 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP4 mRNA

NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138

G

dual specificity phosphatase 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP5 mRNA

NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818

G

dual specificity phosphatase 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of DUSP6 mRNA

NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185

G

E2F transcription factor 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F2 mRNA

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of E2F7 mRNA

NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFEMP2 mRNA

NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414

G

ephrin A3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EFNA3 mRNA

NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736

G

epidermal growth factor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EGF mRNA

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

increases phosphorylation

sotorasib results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 4E family member 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EIF4E3 mRNA

NCBI chr 4:132,258,502...132,301,808
Ensembl chr 4:132,258,502...132,301,808

G

E74 like ETS transcription factor 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ELF5 mRNA

NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973

G

ELMO domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ELMOD1 mRNA

NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:54,298,363...54,355,140

G

enolase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENO2 mRNA

NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980

G

enolase 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENO4 mRNA

NCBI chr 1:258,096,406...258,119,811
Ensembl chr 1:258,096,432...258,128,984

G

ectonucleotide pyrophosphatase/phosphodiesterase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ENPP1 mRNA

NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715

G

ectonucleoside triphosphate diphosphohydrolase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ENTPD2 mRNA

NCBI chr 3:8,213,575...8,219,094
Ensembl chr 3:8,213,663...8,226,866

G

endothelial PAS domain protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

Eph receptor A3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA3 mRNA

NCBI chr11:1,138,485...1,474,102
Ensembl chr11:1,140,985...1,473,900

G

Eph receptor A8

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPHA8 mRNA

NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399

G

epiplakin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EPPK1 mRNA

NCBI chr 7:107,816,919...107,842,946
Ensembl chr 7:107,817,693...107,831,159

G

endoplasmic reticulum aminopeptidase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ERAP1 mRNA

NCBI chr 2:3,931,817...3,970,735
Ensembl chr 2:3,931,904...3,972,447

G

ETS repressor factor like

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERFL mRNA

NCBI chr 1:80,521,378...80,526,262
Ensembl chr 1:80,521,854...80,526,262

G

endoplasmic reticulum oxidoreductase 1 alpha

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ERO1A mRNA

NCBI chr15:18,495,037...18,530,440
Ensembl chr15:18,492,945...18,530,478

G

epithelial splicing regulatory protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ESRP1 mRNA

NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062

G

ETS variant transcription factor 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of ETV2 mRNA

NCBI chr 1:85,890,562...85,894,025
Ensembl chr 1:85,890,559...85,893,431

G

ETS variant transcription factor 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ETV4 mRNA

NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974

G

ecotropic viral integration site 2A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EVI2A mRNA

NCBI chr10:64,485,760...64,489,660
Ensembl chr10:64,485,200...64,489,843

G

exocyst complex component 3-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L1 mRNA

NCBI chr19:33,166,836...33,174,371
Ensembl chr19:33,166,837...33,172,486

G

exocyst complex component 3-like 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of EXOC3L4 mRNA

NCBI chr 6:130,452,680...130,466,684
Ensembl chr 6:130,452,661...130,466,683

G

exophilin 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of EXPH5 mRNA

NCBI chr 8:53,698,825...53,775,371
Ensembl chr 8:53,698,852...53,773,169

G

F2R like trypsin receptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

family with sequence similarity 107, member B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM107B mRNA

NCBI chr17:74,478,608...74,685,027
Ensembl chr17:74,478,608...74,684,989

G

family with sequence similarity 186, member B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAM186B mRNA

NCBI chr 7:130,408,830...130,424,261
Ensembl chr 7:130,408,830...130,424,261

G

family with sequence similarity 241 member A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FAM241A mRNA

NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242

G

FAT atypical cadherin 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FAT2 mRNA

NCBI chr10:39,364,072...39,456,324
Ensembl chr10:39,364,073...39,456,216

G

F-box protein 36

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FBXO36 mRNA

NCBI chr 9:86,042,522...86,107,220
Ensembl chr 9:86,040,862...86,107,229

G

ferredoxin reductase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FDXR mRNA

NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658

G

fibroblast growth factor 19

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

FHF complex subunit HOOK interacting protein 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FHIP1A mRNA

NCBI chr 2:171,016,951...171,265,715
Ensembl chr 2:171,021,246...171,265,848

G

flagellum associated containing coiled-coil domains 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLACC1 mRNA

NCBI chr 9:60,315,581...60,343,692
Ensembl chr 9:60,315,582...60,343,648

G

filamin C

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FLNC mRNA

NCBI chr 4:58,034,088...58,061,882
Ensembl chr 4:58,034,189...58,061,844

G

formin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FMN1 mRNA

NCBI chr 3:100,101,103...100,485,652
Ensembl chr 3:100,134,549...100,479,220

G

fibronectin type III domain containing 11

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FNDC11 mRNA

NCBI chr 3:168,330,607...168,333,111
Ensembl chr 3:168,330,602...168,334,617

G

forkhead box D4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FOXD4 mRNA

NCBI chr 1:222,557,494...222,559,189
Ensembl chr 1:222,557,360...222,559,159

G

forkhead box Q1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FOXQ1 mRNA

NCBI chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377
Ensembl chr17:32,912,744...32,915,377

G

FERM domain containing 4B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FRMD4B mRNA

NCBI chr 4:129,895,401...130,222,070
Ensembl chr 4:129,895,708...130,084,197

G

fascin actin-bundling protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

fucosyltransferase 11

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of FUT11 mRNA

NCBI chr15:3,598,768...3,602,328
Ensembl chr15:3,598,758...3,602,356

G

FYN binding protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of FYB2 mRNA

NCBI chr 5:119,677,116...119,800,911
Ensembl chr 5:119,677,204...119,800,910

G

GRB2-associated binding protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAB2 mRNA

NCBI chr 1:151,429,844...151,625,708
Ensembl chr 1:151,429,695...151,625,031

G

glutamate decarboxylase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

galactose-3-O-sulfotransferase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GAL3ST1 mRNA

NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

growth arrest specific 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GAS6 mRNA

NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904

G

golgi associated kinase 1B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GASK1B mRNA

NCBI chr 2:165,047,689...165,112,479
Ensembl chr 2:165,047,684...165,112,477

G

guanylate binding protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

glucokinase regulator

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GCKR mRNA

NCBI chr 6:25,044,592...25,075,834
Ensembl chr 6:25,045,100...25,075,654

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

ganglioside-induced differentiation-associated-protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GDAP1 mRNA

NCBI chr 5:1,932,613...1,951,691
Ensembl chr 5:1,932,613...2,030,061

G

growth hormone receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GHR mRNA

NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735

G

GIPC PDZ domain containing family, member 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GIPC3 mRNA

NCBI chr 7:8,374,941...8,383,281

G

gastric inhibitory polypeptide receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GIPR mRNA

NCBI chr 1:78,804,287...78,814,462
Ensembl chr 1:78,805,593...78,814,462

G

gap junction protein, beta 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GJB3 mRNA

NCBI chr 5:139,649,227...139,654,970
Ensembl chr 5:139,649,195...139,654,980

G

gap junction protein, beta 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GJB4 mRNA

NCBI chr 5:139,675,776...139,679,551
Ensembl chr 5:139,675,780...139,679,667

G

glycine decarboxylase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLDC mRNA

NCBI chr 1:227,883,249...227,962,119
Ensembl chr 1:227,883,249...227,962,097

G

glutamate-ammonia ligase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GLUL mRNA

NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108

G

glycoprotein nmb

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPNMB mRNA

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

G protein-coupled receptor 146

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR146 mRNA

NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206

G

G protein-coupled receptor 37-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR37L1 mRNA

NCBI chr13:46,598,574...46,605,421
Ensembl chr13:46,598,578...46,605,421

G

G protein-coupled receptor 39

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GPR39 mRNA

NCBI chr13:37,115,258...37,327,312
Ensembl chr13:37,115,102...37,328,267

G

G protein-coupled receptor 87

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GPR87 mRNA

NCBI chr 2:143,439,741...143,440,901
Ensembl chr 2:143,439,735...143,458,190

G

GRAM domain containing 1B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRAMD1B mRNA

NCBI chr 8:40,654,492...40,893,869
Ensembl chr 8:40,659,182...40,893,925

G

growth factor receptor bound protein 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRB7 mRNA

NCBI chr10:83,443,387...83,453,057
Ensembl chr10:83,444,004...83,453,052

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GRIN2D mRNA

NCBI chr 1:96,306,871...96,346,994
Ensembl chr 1:96,308,365...96,344,793

G

gasdermin C

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GSDMC mRNA

NCBI chr 7:95,594,015...95,606,106
Ensembl chr 7:95,594,015...95,611,344

G

GTF2I repeat domain containing 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of GTF2IRD2 mRNA

NCBI chr12:22,497,767...22,536,455
Ensembl chr12:22,498,091...22,536,263

G

guanylate cyclase activator 1B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of GUCA1B mRNA

NCBI chr 9:13,599,619...13,607,455
Ensembl chr 9:13,599,619...13,607,455

G

H1.2 linker histone, cluster member

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H1-2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

histidine ammonia lyase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HAL mRNA

NCBI chr 7:28,007,449...28,037,701
Ensembl chr 7:28,006,972...28,037,701

G

hyaluronan and proteoglycan link protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HAPLN2 mRNA

NCBI chr 2:173,488,909...173,496,824
Ensembl chr 2:173,491,160...173,496,588

G

hyaluronan synthase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HAS3 mRNA

NCBI chr19:34,768,421...34,782,170
Ensembl chr19:34,771,982...34,782,592

G

heparin-binding EGF-like growth factor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

HECT, C2 and WW domain containing E3 ubiquitin protein ligase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HECW2 mRNA

NCBI chr 9:55,359,462...55,753,106
Ensembl chr 9:55,365,203...55,580,327

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HERC6 mRNA

NCBI chr 4:87,524,470...87,566,895
Ensembl chr 4:87,524,493...87,581,744

G

hes-related family bHLH transcription factor with YRPW motif 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HEY1 mRNA

NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312

G

hes-related family bHLH transcription factor with YRPW motif-like

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HEYL mRNA

NCBI chr 5:135,508,160...135,525,152
Ensembl chr 5:135,508,160...135,525,152

G

HIC ZBTB transcriptional repressor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HIC1 mRNA

NCBI chr10:60,014,520...60,019,475
Ensembl chr10:60,011,528...60,019,475

G

hypoxia inducible lipid droplet-associated

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HILPDA mRNA

NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557

G

histone cluster 1 H2A family member H

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC11 mRNA

NCBI chr17:41,384,521...41,385,018

G

histone cluster 1 H2A family like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

HIVEP zinc finger 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HIVEP2 mRNA

NCBI chr 1:8,358,205...8,555,993
Ensembl chr 1:8,359,289...8,555,993

G

hexokinase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

hexokinase domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HKDC1 mRNA

NCBI chr20:30,335,322...30,373,792
Ensembl chr20:30,335,628...30,373,867

G

4-hydroxy-2-oxoglutarate aldolase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOGA1 mRNA

NCBI chr 1:240,856,991...240,884,243
Ensembl chr 1:240,857,126...240,884,568

G

homeo box A13

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXA13 mRNA

NCBI chr 4:81,358,956...81,361,091
Ensembl chr 4:81,358,956...81,361,091

G

homeo box B9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HOXB9 mRNA

NCBI chr10:81,237,312...81,240,818
Ensembl chr10:81,237,312...81,240,818

G

homeo box C4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HOXC4 mRNA

NCBI chr 7:134,135,279...134,173,133
Ensembl chr 7:134,170,591...134,173,133

G

hippocalcin-like 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HPCAL4 mRNA

NCBI chr 5:135,454,477...135,466,417
Ensembl chr 5:135,454,540...135,466,416

G

heparan sulfate-glucosamine 3-sulfotransferase 3B1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HS3ST3B1 mRNA

NCBI chr10:48,561,473...48,593,970
Ensembl chr10:48,561,473...48,593,970

G

hydroxysteroid (17-beta) dehydrogenase 14

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HSD17B14 mRNA

NCBI chr 1:96,029,224...96,039,577
Ensembl chr 1:96,029,284...96,039,883

G

heat shock protein family A (Hsp70) member 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HSPA1A mRNA

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

HtrA serine peptidase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HTRA1 mRNA

NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379

G

hormonally upregulated Neu-associated kinase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of HUNK mRNA

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:29,640,775...29,757,526

G

hyaluronidase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of HYAL1 mRNA

NCBI chr 8:108,250,668...108,254,519
Ensembl chr 8:108,250,667...108,260,210

G

interferon-induced protein 35

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IFI35 mRNA

NCBI chr10:86,381,023...86,389,279
Ensembl chr10:86,381,010...86,389,952

G

interferon, lambda receptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IFNLR1 mRNA

NCBI chr 5:147,919,547...147,942,328
Ensembl chr 5:147,919,908...147,942,332

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IGF2BP3 mRNA

NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865

G

insulin-like growth factor binding protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 1 beta

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor accessory protein-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL1RAPL1 mRNA

NCBI chr X:51,371,969...52,876,726
Ensembl chr X:51,378,215...52,876,772

G

interleukin 6 receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IL6R mRNA

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

inka box actin regulator 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INKA1 mRNA

NCBI chr 8:108,674,263...108,675,953
Ensembl chr 8:108,674,263...108,675,953

G

inositol polyphosphate-5-phosphatase D

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of INPP5D mRNA

NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746

G

inhibitory synaptic factor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of INSYN1 mRNA

NCBI chr 8:58,904,153...58,914,850
Ensembl chr 8:58,904,153...58,914,843

G

IQ motif and ankyrin repeat containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IQANK1 mRNA

NCBI chr 7:107,724,962...107,759,163
Ensembl chr 7:107,724,997...107,759,162

G

IQ motif containing N

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IQCN mRNA

NCBI chr16:18,716,519...18,733,971
Ensembl chr16:18,716,519...18,726,261

G

interleukin-1 receptor-associated kinase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of IRAK2 mRNA

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602

G

interferon regulatory factor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of IRF1 mRNA

NCBI chr10:37,917,155...37,924,166
Ensembl chr10:37,916,670...37,924,166

G

isthmin 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ISM2 mRNA

NCBI chr 6:106,921,213...106,944,291
Ensembl chr 6:106,926,175...106,944,514

G

integrin subunit alpha 10

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA10 mRNA

NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:184,182,869...184,202,172

G

integrin subunit alpha 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha X

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGAX mRNA

NCBI chr 1:182,709,653...182,740,709
Ensembl chr 1:182,719,609...182,740,698

G

integrin subunit beta 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB3 mRNA

NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679

G

integrin subunit beta 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ITGB4 mRNA

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

Janus kinase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAK3 mRNA

NCBI chr16:18,386,330...18,398,542
Ensembl chr16:18,386,405...18,398,536

G

junctional adhesion molecule 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of JAM2 mRNA

NCBI chr11:23,830,820...23,880,071
Ensembl chr11:23,831,106...23,880,063

G

potassium inwardly-rectifying channel, subfamily J, member 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KCNJ4 mRNA

NCBI chr 7:111,047,097...111,074,151
Ensembl chr 7:111,047,094...111,074,151

G

potassium two pore domain channel subfamily K member 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KCNK5 mRNA

NCBI chr15:4,122,442...4,164,718
Ensembl chr15:4,122,442...4,164,718

G

lysine demethylase 7A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KDM7A mRNA

NCBI chr 4:67,899,407...67,974,264
Ensembl chr 4:67,904,307...67,966,998

G

KIAA1755 ortholog

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KIAA1755 mRNA

NCBI chr 3:146,850,558...146,884,238
Ensembl chr 3:146,850,557...146,884,871

G

kinesin family member 17

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KIF17 mRNA

NCBI chr 5:150,482,288...150,521,471
Ensembl chr 5:150,481,578...150,519,638

G

KLF transcription factor 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of KLF7 mRNA

NCBI chr 9:65,433,683...65,526,372
Ensembl chr 9:65,437,167...65,526,261

G

kelch domain containing 7A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KLHDC7A mRNA

NCBI chr 5:152,218,604...152,224,707
Ensembl chr 5:152,221,033...152,224,551

G

kelch domain containing 7B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KLHDC7B mRNA

NCBI chr 7:120,452,081...120,455,737
Ensembl chr 7:120,453,932...120,455,737

G

KRAS proto-oncogene, GTPase

increases response to substance
affects binding
multiple interactions

KRAS protein mutant form results in increased susceptibility to sotorasib
sotorasib binds to KRAS protein mutant form
KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK1 protein]; KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK3 protein]

NCBI chr 4:178,185,418...178,218,484

G

keratin 15

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT15 mRNA

NCBI chr10:85,066,797...85,070,614
Ensembl chr10:85,066,802...85,171,799

G

keratin 7

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT7 mRNA

NCBI chr 7:132,528,881...132,545,052
Ensembl chr 7:132,528,895...132,545,052

G

keratin 86

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of KRT86 mRNA

NCBI chr 7:132,591,489...132,598,142
Ensembl chr 7:132,591,545...132,598,021

G

ladinin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAD1 mRNA

NCBI chr13:47,249,605...47,263,967
Ensembl chr13:47,249,605...47,263,967

G

laminin subunit alpha 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA2 mRNA

NCBI chr 1:17,672,675...18,320,641
Ensembl chr 1:17,672,536...18,320,530

G

laminin subunit alpha 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMA4 mRNA

NCBI chr20:42,392,268...42,533,347
Ensembl chr20:42,392,268...42,533,347

G

laminin subunit gamma 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LAMC2 mRNA

NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200

G

lysosomal protein transmembrane 5

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAPTM5 mRNA

NCBI chr 5:143,087,759...143,109,807
Ensembl chr 5:143,087,759...143,109,807

G

linker for activation of T cells family, member 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LAT2 mRNA

NCBI chr12:22,104,173...22,118,294
Ensembl chr12:22,104,219...22,118,288

G

lymphocyte cytosolic protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LCP1 mRNA

NCBI chr15:50,443,300...50,544,682
Ensembl chr15:50,488,149...50,544,680

G

low density lipoprotein receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

low density lipoprotein receptor class A domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LDLRAD1 mRNA

NCBI chr 5:121,984,245...122,000,941
Ensembl chr 5:121,991,690...122,000,944

G

low density lipoprotein receptor class A domain containing 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LDLRAD4 mRNA

NCBI chr18:61,519,253...61,848,403
Ensembl chr18:61,521,428...61,843,238

G

LEM domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LEMD1 mRNA

NCBI chr13:43,631,705...43,697,765
Ensembl chr13:43,665,926...43,697,948

G

galectin 9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGALS9 mRNA

NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045

G

leucine-rich repeat LGI family, member 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LGI3 mRNA

NCBI chr15:45,605,611...45,612,739
Ensembl chr15:45,605,611...45,612,739

G

LIM homeobox 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX1 mRNA

NCBI chr10:69,396,829...69,403,617
Ensembl chr10:69,396,829...69,403,617

G

LIM homeobox 6

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LHX6 mRNA

NCBI chr 3:19,432,439...19,456,268
Ensembl chr 3:19,433,494...19,456,061

G

lipase G, endothelial type

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPG mRNA

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260

G

lipase H

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LIPH mRNA

NCBI chr11:79,032,229...79,081,625
Ensembl chr11:79,033,312...79,081,625

G

LON peptidase N-terminal domain and ring finger 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LONRF3 mRNA

NCBI chr X:115,565,214...115,603,886
Ensembl chr X:115,565,267...115,598,809

G

lysyl oxidase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

LRAT domain containing 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LRATD2 mRNA

NCBI chr 7:92,376,713...92,387,045
Ensembl chr 7:92,362,194...92,388,189

G

leucine rich repeat containing 37A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LRRC37A3 mRNA

NCBI chr10:88,395,837...88,433,519
Ensembl chr10:88,396,663...88,433,323

G

lipolysis stimulated lipoprotein receptor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LSR mRNA

NCBI chr 1:86,185,769...86,201,952
Ensembl chr 1:86,186,431...86,201,952

G

latent transforming growth factor beta binding protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LTBP1 mRNA

NCBI chr 6:20,029,629...20,425,339
Ensembl chr 6:20,029,629...20,425,349

G

latent transforming growth factor beta binding protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LTBP2 mRNA

NCBI chr 6:104,429,947...104,530,498
Ensembl chr 6:104,429,947...104,526,208

G

lysosomal trafficking regulator

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of LYST mRNA

NCBI chr17:86,241,384...86,443,501
Ensembl chr17:86,241,384...86,443,480

G

leucine zipper tumor suppressor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of LZTS1 mRNA

NCBI chr16:20,542,756...20,598,204
Ensembl chr16:20,542,809...20,598,203

G

mitotic arrest deficient 1 like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAD1L1 mRNA

NCBI chr12:14,320,892...14,630,750
Ensembl chr12:14,320,892...14,630,703

G

MAF bZIP transcription factor F

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

microtubule-associated protein 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MAP1A mRNA

NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899

G

mitogen activated protein kinase kinase kinase kinase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MAP4K1 mRNA

NCBI chr 1:84,270,951...84,292,496
Ensembl chr 1:84,271,069...84,292,493

G

mitogen activated protein kinase 1

multiple interactions
decreases phosphorylation

KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

sotorasib results in decreased phosphorylation of MAPK3 protein
KRAS protein affects the reaction [sotorasib results in decreased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

membrane associated ring-CH-type finger 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MARCHF4 mRNA

NCBI chr 9:74,078,437...74,196,070
Ensembl chr 9:74,078,434...74,198,199

G

microtubule associated serine/threonine kinase family member 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MAST4 mRNA

NCBI chr 2:33,893,241...34,483,682
Ensembl chr 2:33,894,436...34,483,723

G

matrilin 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

multiple C2 and transmembrane domain containing 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MCTP1 mRNA

NCBI chr 2:6,071,408...6,761,833
Ensembl chr 2:6,065,808...6,761,833

G

MAM domain containing glycosylphosphatidylinositol anchor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MDGA1 mRNA

NCBI chr20:7,900,327...7,964,309
Ensembl chr20:7,904,358...7,963,471

G

Meis homeobox 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MEIS1 mRNA

NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265

G

mesoderm specific transcript

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MEST mRNA

NCBI chr 4:59,354,445...59,364,919
Ensembl chr 4:59,354,447...59,366,145

G

hypothetical protein LOC681210

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of C6ORF118 mRNA

NCBI chr 1:51,740,328...51,764,041
Ensembl chr 1:51,740,330...51,763,989

G

midline 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MID1 mRNA

NCBI chr X:24,116,674...24,491,205
Ensembl chr X:24,120,293...24,248,353

G

mast cell immunoglobulin-like receptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MILR1 mRNA

NCBI chr10:91,684,288...91,705,284
Ensembl chr10:91,687,831...91,705,282

G

melanophilin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MLPH mRNA

NCBI chr 9:91,507,410...91,542,984
Ensembl chr 9:91,507,591...91,542,983

G

matrix metallopeptidase 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP1 mRNA

NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097

G

matrix metallopeptidase 12

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611

G

matrix metallopeptidase 13

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 14

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP14 mRNA

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 19

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MMP19 mRNA

NCBI chr 7:1,221,229...1,229,555
Ensembl chr 7:1,221,343...1,229,555

G

matrix metallopeptidase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP3 mRNA

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

matrix metallopeptidase 9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

MORN repeat containing 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MORN3 mRNA

NCBI chr12:33,505,654...33,529,918
Ensembl chr12:33,514,230...33,529,931

G

myelin protein zero-like 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MPZL2 mRNA

NCBI chr 8:45,348,285...45,359,298
Ensembl chr 8:45,348,285...45,359,298

G

melanocortin 2 receptor accessory protein 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MRAP2 mRNA

NCBI chr 8:88,088,293...88,144,636
Ensembl chr 8:88,088,272...88,143,886

G

mucin 3A, cell surface associated

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MUC3A mRNA

NCBI chr12:19,450,679...19,454,753
Ensembl chr12:19,446,094...19,460,522

G

mucin 5B, oligomeric mucus/gel-forming

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MUC5B mRNA

NCBI chr 1:196,916,861...196,948,830
Ensembl chr 1:196,916,825...196,949,250

G

myosin binding protein H

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYBPH mRNA

NCBI chr13:45,653,156...45,660,893
Ensembl chr13:45,653,234...45,660,893

G

myosin, heavy chain 15

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYH15 mRNA

NCBI chr11:51,621,924...51,763,037
Ensembl chr11:51,622,413...51,762,971

G

myosin X

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO10 mRNA

NCBI chr 2:76,100,989...76,305,619
Ensembl chr 2:76,100,987...76,303,030

G

myosin XVA

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO15A mRNA

NCBI chr10:45,277,619...45,335,953
Ensembl chr10:45,278,737...45,335,340

G

myosin XVB

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO15B mRNA

NCBI chr10:101,088,734...101,126,159
Ensembl chr10:101,104,209...101,125,693

G

myosin VC

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of MYO5C mRNA

NCBI chr 8:75,989,497...76,066,485
Ensembl chr 8:75,989,528...76,066,483

G

myosin VIIb

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of MYO7B mRNA

NCBI chr18:23,588,307...23,669,841
Ensembl chr18:23,588,307...23,669,809

G

Nedd4 binding protein 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of N4BP3 mRNA

NCBI chr10:35,898,031...35,906,704
Ensembl chr10:35,899,096...35,907,001

G

neuron navigator 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NAV3 mRNA

NCBI chr 7:45,052,206...45,840,471
Ensembl chr 7:45,054,296...45,840,698

G

N-myc downstream regulated 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDRG1 mRNA

NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880

G

NDRG family member 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDRG4 mRNA

NCBI chr19:9,351,408...9,387,398
Ensembl chr19:9,351,404...9,386,914

G

NADH:ubiquinone oxidoreductase core subunit V2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NDUFV2 mRNA

NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713

G

neural precursor cell expressed, developmentally down-regulated 9

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NEDD9 mRNA

NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019

G

nestin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NES mRNA

NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777

G

neuralized E3 ubiquitin protein ligase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NEURL3 mRNA

NCBI chr 9:38,494,486...38,503,352
Ensembl chr 9:38,494,489...38,502,649

G

neuronal guanine nucleotide exchange factor

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NGEF mRNA

NCBI chr 9:88,146,956...88,244,454
Ensembl chr 9:88,146,956...88,244,914

G

NHS-like 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NHSL1 mRNA

NCBI chr 1:12,956,525...13,188,580
Ensembl chr 1:12,956,021...13,187,547

G

NHS-like 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NHSL2 mRNA

NCBI chr X:66,969,953...67,209,464
Ensembl chr X:66,970,151...67,200,911

G

NIM1 serine/threonine protein kinase

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NIM1K mRNA

NCBI chr 2:51,670,764...51,714,782
Ensembl chr 2:51,670,772...51,714,762

G

NIPA-like domain containing 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NIPAL4 mRNA

NCBI chr10:30,583,926...30,600,640
Ensembl chr10:30,583,926...30,600,640

G

NK2 homeobox 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NKX2-1 mRNA

NCBI chr 6:73,996,601...74,001,483
Ensembl chr 6:73,996,601...73,999,791

G

neuroligin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NLGN1 mRNA

NCBI chr 2:108,256,236...109,181,530
Ensembl chr 2:108,257,824...109,002,464

G

NLR family, pyrin domain containing 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NLRP1 mRNA

NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180

G

nicotinamide nucleotide adenylyltransferase 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NMNAT2 mRNA

NCBI chr13:65,105,950...65,277,350
Ensembl chr13:65,105,950...65,278,484

G

noggin

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NOG mRNA

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

notch receptor 4

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NOTCH4 mRNA

NCBI chr20:4,160,362...4,184,466
Ensembl chr20:4,160,445...4,184,465

G

neuronal PAS domain protein 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPAS1 mRNA

NCBI chr 1:77,167,375...77,187,887
Ensembl chr 1:77,167,381...77,186,762

G

neuropeptide B

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NPB mRNA

NCBI chr10:105,883,992...105,887,689
Ensembl chr10:105,874,708...105,887,254

G

natriuretic peptide receptor 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

neuronal pentraxin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NPTX1 mRNA

NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367

G

nuclear receptor subfamily 1, group D, member 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NR1D1 mRNA

NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705

G

nuclear receptor subfamily 3, group C, member 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NR3C2 mRNA

NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885

G

neuronal regeneration related protein

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NREP mRNA

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

neuropilin 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of NRP1 mRNA

NCBI chr19:56,359,455...56,514,628
Ensembl chr19:56,359,455...56,513,633

G

neuropilin 2

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NRP2 mRNA

NCBI chr 9:64,122,815...64,238,007
Ensembl chr 9:64,123,132...64,237,958

G

5' nucleotidase, ecto

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

neurotensin receptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NTSR1 mRNA

NCBI chr 3:167,606,215...167,656,371
Ensembl chr 3:167,606,215...167,656,377

G

neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of NYAP1 mRNA

NCBI chr12:18,956,192...18,967,624
Ensembl chr12:18,956,268...18,967,543

G

2'-5' oligoadenylate synthetase 1A

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OAS1 mRNA

NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517

G

2'-5'-oligoadenylate synthetase 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OAS3 mRNA

NCBI chr12:35,779,028...35,802,781
Ensembl chr12:35,779,022...35,802,781

G

2'-5'-oligoadenylate synthetase-like

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in increased expression of OASL mRNA

NCBI chr12:41,682,900...41,695,641
Ensembl chr12:41,682,900...41,695,641

G

obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of OBSCN mRNA

NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723

G

one cut homeobox 3

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of ONECUT3 mRNA

NCBI chr 7:9,199,997...9,219,303
Ensembl chr 7:9,200,035...9,219,158
Ensembl chr 7:9,200,035...9,219,158

G

oxidative stress induced growth inhibitor 1

multiple interactions

[sotorasib co-treated with trametinib co-treated with NVP-BKM120] results in decreased expression of OSGIN1 mRNA